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Abstract The role of protein kinase C (PKC) and 
p42MAP klnase signaling in the regulation of proliferation and 
apoptosis was investigated in freshly isolated and primary 
cultured rat hepatocytes. Acute treatment of freshly isolated 
hepatocytes with phenylephrine and EGF caused rapid phasic 
activations of p42MAP kinase and JNKl. Acute pre-treatment of 
hepatocytes with the PKC inhibitors sphingosine, chelerythrine 
and Ais-indolylmaleimide abolished the ability of phenylephrine, 
but not EGF, to activate p42MAP k!nase and JNKl. Acute pre-
treatments with all of the PKC inhibitors alone increased JNKl 
basal activity ~ 2-fold. Acute treatments of primary cultures of 
hepatocytes with an inhibitor of MEK1 activation (PD98059) 
also caused inhibition of p42MAP klnase and a ~ 2-fold activation 
of JNKl. These data demonstrate that PKC can function as both 
a proximal activator and a distal inhibitor of signaling through 
the JNK1/SAP kinase pathway. Treatments (4 h) of primary 
cultured hepatocytes with sphingosine, chelerythrine, Ws-indo-
lylmaleimide and PD98059 did not induce apoptosis as judged by 
propidium iodide staining. Similar acute treatments of HepG2 
cells rapidly induced cell death. These data demonstrate that 
acute inhibition of either PKC or p 42
M A P k i n a s c function is 
sufficient to rapidly induce apoptosis in transformed, but not in 
non-transformed hepatocytes. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The mechanisms by which non-transformed cells regulate 
their ability to differentiate, proliferate, or undergo apoptosis 
are poorly understood. To better understand these processes, 
we have examined the regulation of signal transduction cas-
cades in primary cultures of rat hepatocytes. 
The liver is the only organ of the body which can fully 
regenerate its cell mass after injury [1-3]. During regeneration, 
hepatocytes acquire altered sensitivity/responsiveness towards 
multiple agonists, including a reciprocal decrease and increase, 
respectively, in the levels of ai-adrenergic and f^-adrenergic 
receptors [4-6]. We recently demonstrated that such altera-
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tions in signaling lead to a decrease in the ability of epineph-
rine and other factors to activate protein kinase C (PKC), 
Raf-1, and p42/44
MAPkinase, and concurrently lead to an in-
crease in the ability of epinephrine and other factors to acti-
vate JNKl (c-Jun NH2-terminal kinase), and p38
S A P k i n a s c 
(p38-reactivating kinase) [6]. 
The JNKl/stress-activated protein (SAP) kinase cascade 
was initially discovered in yeast and has subsequently been 
characterized in mammalian cells [7-10]. Apoptotic responses 
have been asssociated with the cytotoxic lipid messengers cer-
amide [11,12] and sphingosine [8,13] in human myeloid leuke-
mia cells. Activation of the SAP kinases, JNKl and JNK2 
have been directly implicated in the ceramide-related apopto-
sis [14,15], although the pathway linking ceramide to the SAP 
kinase cascade has not been completely delineated. In con-
trast, sphingosine-related cytotoxicity is most commonly at-
tributed to proximal inhibition of PKC [16]. Recently we have 
found that, unlike ceramide, sphingosine does not engage 
JNKl to promote apoptosis [17], indicating that the lethal 
actions of ceramide and sphingosine are subserved by distinct 
signaling mechanisms. In hepatocytes, however, little is 
known about the co-ordinated mechanisms by which altera-
tions in receptor signaling, PKC activity, and the activities of 
p42MAP kmasc and JNKl are altered upon liver regeneration or 
hepatocellular transformation. Still less is known as to how 
these alterations effect the actions of cytotoxic lipid second 
messengers and the contributions of these messengers towards 
regulating systems governing the initiation of apoptosis 
[18,19]. 
In the present studies, we have examined the role of PKC in 
the regulation of p42MAP kmase and JNKl by hormonal ago-
nists and lipid signaling molecules, and the roles PKC and 
p42MAPkmase play in proliferative and apoptotic signaling 
processes in primary isolates of hepatocytes. Our findings 
strongly suggest that the balance of proliferative and apoptotic 
signals are integrated at multiple levels, and that examination 
of signaling via any single pathway cannot be used to explain 
definitively the physiological regulation of cell survival. 
2. Materials and methods 
2.1. Materials 
Male Sprague-Dawley rats (200 g) had access to food and water ad 
libitum [5]. Anti-JNKl/2 (mostly immunoprecipitating JNKl, sc-
571AC) antibody was from Santa Cruz Biotechnology (Santa Cruz 
Biotechnologies, CA) and anti-p42MAF hnaae antibodies were a kind 
gift from Dr. M.J. Weber (University of Virginia, Charlottesville, 
VA). Hormones, growth factors, and propidium iodide (PI) were pur-
chased from Sigma Chemicals (St. Louis, MO). Radiolabelled 
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[y-32P]ATP and [3H]thymidine were from NEN. GST-c-Jun (aal-169) 
was synthesized in Escherichia coli and purified on GST-Sepharose. 
Protein preparations of all other reagents were as described in 
[6,21,22]. Specific kinase domain inhibitors of protein kinase C, bis-
indolyl-maleimaide GF109203X [23,24], chelerythrine [18], and the 
MEK1 activation inhibitor PD98059 [25] were from Calbiochem. 
Sphingosine was from Biomol (Plymouth Meeting, MA). 
2.2. Preparation of hepatocytes 
Rats were anesthetized by i.p. injection of sodium pentabarbital (50 
mg/kg), and the lower thorax and abdomen was shaved to remove fur. 
A small (3 cm) vertical mid-line incision was made in the abdominal 
wall from just below the costal margin/xiphoid process. Hepatocytes 
were prepared by cannulation of the portal vein and collagenase per-
fusion of the liver. A cannula was inserted into the portal vein and 
two ties tightened so as to occlude the inferior vena cava, and to 
secure the cannula in the portal vein. Gassed Krebs-Henseleit buffer 
(95% air, 5% C0 2 , 37°C) containing 0.3 mM EGTA (to prevent clot-
ting), was passed through the liver (20 ml/min flow rate) to wash out 
erythrocytes; a second cannula was inserted into the inferior vena 
cava via the right atrium of the heart, and also secured with a tie, 
to act as a drain. Livers were washed sequentially with 200 ml of this 
buffer, followed by 200 ml of the same media omitting EGTA, and 
including 0.5 mg/ml collagenase. The liver was then removed and 
filtered through sterile muslin into a sterile container and washed 
(X 3) with Krebs-Henseleit buffer. Hepatocytes were then resuspended 
to 5 mg wet weight/ml serum-free Krebs-Henseleit buffer containing 
1.5% (w/v) Difco gelatin, and were incubated at 37°C under an atmo-
sphere of 5% CO2 in O2 with continuous rotory shaking at 100 cycles/ 
min. After a 30 min pre-incubation to stabilize basal levels of protein 
kinase activities (data not shown), aliquots were taken from the first 
portion and used immediately for experiments to determine hormonal 
effects on protein kinase activities [6]. 
2.3. Treatment of freshly isolated hepatocytes and primary cultures 
of hepatocytes and HepG2 cells with hormones and cell 
homogenization 
Hormones were added to microfuge tubes containing hepatocytes (5 
mg wet weight in 1 ml buffer, 1 mg total protein used per immuno-
precipitate) in the absence of serum. Primary cultures of hepatocytes 
and HepG2 cells were cultured in 12-well plates or 20 mm dishes 
(2X105 cells) and grown in DMEM containing 10% (w/v) fetal calf 
serum (2 mg wet weight cells/dish, 1 mg total protein used per immu-
noprecipitate) and additions made to these cells after 30 min serum 
starvation in 5 ml of DMEM medium. Hormones were added to give 
final specified concentrations (see text and figure legends), vortexed/ 
mixed to ensure complete mixing, and incubated for the specified 
times at 37°C in a water bath or cell culture incubator. Cells were 
pretreated with protein kinase inhibitors (20 min) or lipids (15 min) 
prior to hormonal additions. Thirty seconds prior to termination, 
tubes were removed from the bath, placed in a microfuge, the cells 
pelleted, and the supernatant removed. Plated cells were aspirated 
followed by immediate homogenization. Cells were homogenized in 
1 ml of ice-cold buffer A (25 mM HEPES, pH 7.4 at 4°C, 5 mM 
EDTA, 5 mM EGTA, 5 mM benzamidine, 1 mM phenylmethyl sul-
phonylfluoride, 1 mg/ml soybean trypsin inhibitor, 40 ug/ml pepsta-
tin A, 40 ug/ml E64, 40 ug/ml aprotinin, 1 uM Microcystin-LR, 0.5 
mM sodium orthovanadate, 0.5 mM sodium pyrophosphate, 0.05% 
(w/v) sodium deoxycholate, 1% (v/v) Triton X100, 0.1% (v/v) 2-mer-
captoethanol), with trituration using a P1000 pipette to lyse the cells. 
Homogenates were stored on ice (5 min) prior to clarification by 
centrifugation (4°C). 
2.4. Immunoprecipitations from homogenates 
Fifty microliters of Protein A agarose (Ag) slurry (25 ja.1 bead vol-
ume) was washed twice with 1 ml of PBS containing 0.1% (v/v) 
Tween-20, and resuspended in 0.1 ml of the same buffer. Antibodies 
(2 ug, 20 ul) or serum (20 |xl) were added to each tube and incubated 
(3 h, 4°C). Clarified hepatocyte homogenates (0.5 ml, 1 mg total 
protein) were mixed with Protein A-Ag-conjugated antibody in dup-
licate using gentle agitation (2.5 h, 4°C). Protein A-Ag was recovered 
by centrifugation, the supernatant discarded, and washed (10 min) 
sequentially with 0.5 ml buffer A (twice), PBS and buffer B (25 mM 
HEPES, pH 7.4, 15 mM MgCl2, 0.1 mM Na2V04 , 0.1% (v/v) 2-mer-
captoenthanol). 
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2.5. Assay of p42MAF'kmase activity 
Immunoprecipitates were incubated (final volume 50 ill) with 50 ul 
of buffer B containing 0.2 mM [y-32P]ATP (5000 cpm/pmol), 1 uM 
Microcystin-LR, 0.5 mg/ml myelin basic protein (MBP), which initi-
ated reactions. After 20 min, 40 ul °f the reaction mixtures were 
spotted onto a 2 cm circle of P81 paper (Whatman, Maidstone, 
UK) and immediately placed into 180 mM phosphoric acid. Papers 
were washed 4 times (10 min each) with phosphoric acid, and once 
with acetone, and 32P-incorporation into MBP was quantified by 
liquid scintillation spectroscopy. Pre-immune controls were performed 
to ensure MBP phosphorylation was dependent upon specific immu-
noprecipitation 0 f ^ 2
M " " " [21]. 
2.6. Assay of JNK1 activity 
Immunoprecipitates were incubated (final volume 100 ul) with 2 ul 
(10 ug) of GST-c-Jun (aal-169), and reactions initiated with 98 ul of 
buffer B containing 0.2 mM [y-32P]ATP (5000 cpm/pmol) and 1 uM 
Microcystin-LR. After 30 min, reactions were terminated with sample 
buffer and prepared for SDS-PAGE (10% gel) to quantify 32P-incor-
poration into excised, Coomassie blue-stained GST-c-Jun (aal-169) 
bands by liquid scintillation spectroscopy. Pre-immune control assays 
were performed to ensure GST-c-Jun (aal-169) phosphorylation was 
dependent upon specific immunoprecipitation of JNK1 in the assay 
[26]. 
2.7. Cell culture, and primary culture and assay for DNA synthesis 
in hepatocytes 
HepG2 cells were cultured by established procedures in Dulbecco's 
modified Eagle's medium containing 10% (v/v) fetal calf serum (FCS) 
in 5% (v/v) C0 2 . Hepatocytes isolated from sham-operated or PHX 
rats were cultured on rat-tail collagen (Vitrogen)-coated plastic dishes 
(12x20 mm, 2X 106 cells, 2 mg wet weight) in William's E medium 
and allowed to adhere to the dish. After 2 h the medium was replaced 
and hepatocytes cultured in William's E medium containing 20 uCi of 
[3H]thymidine, 1 nM dexamethasone and 100 nM insulin, in 5% (v/v) 
CO2. Adrenergic drugs, hormonal treatments, and/or protein kinase 
inhibitors were added at the time of the media change. Cells were 
cultured for 48 h, after which time cells were lysed with 0.5 N 
NaOH and DNA precipitated with 12.5% (w/v) TCA (final). Acid 
precipitable material was transferred to glass fiber filters, washed 
with 5% (w/v) TCA, and [3H]thymidine incorporation into DNA 
quantified by liquid scintillation spectrometry [27]. 
2.8. Transcription factor DNA binding assay 
Nuclear extracts are prepared as described [5]. Oligonucleotides are 
32P-labelled with [y-32P]ATP using polynucleotide kinase. Binding re-
action mixtures (20 ill) are incubated at room temperature for 45 min 
containing 1 ng DNA probe and 5 ug nuclear extract in 10 mM Tris-
HC1, pH 7.5, at 25°C, 40 mM NaCl, 1 mM DTT, 1 mM EDTA, 5% 
(v/v) glycerol and 2 ug poly(dl-dC), to inhibit non-specific binding in 
the extract. DNA-protein complexes are resolved by electrophoresis 
through a 4%/8% non-denaturing polyacrylamide gel containing 50 
mM Tris-HCl, 0.38 M glycine and 2 mM EDTA. Gels are dried 
and quantified/processed using a Phosphoimager. 
2.9. Data analysis 
Comparison of the effects of various hormone treatments was done 
using 1-way analysis of variance and a 2-tailed Mest. Differences with 
a P-value of < 0.05 (* and &) were considered statistically significant. 
All bar-graph fold-values and means shown are ± SD from an aver-
age of 2-5 independent experiments (depending upon the figure) are 
shown. 
3. Results and discussion 
Freshly isolated hepatocytes were treated with phenyleph-
rine or E G F , and p42 M A P klnase and J N K 1 activities measured 
in immune-complex kinase assays (Fig. 1). Phenylephrine 
(Fig. 1A) and E G F (Fig. IB) activated p42 M A P kinase and 
J N K 1 with rapid phasic kinetics, with maximal activations 
between 4 and 10 min; maximal stimulations by phenyleph-
rine and E G F were titrated to 10 |0.M and 30 ng/ml for each 
hormone, respectively (data not shown). Acute (20 min) pre-
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Fig. 1. Time course of activation of p42MAPkmase and JNKI by 
phenylephrine (10 uM) (A) and epidermal growth factor (30 ng/ml) 
(B) in freshly isolated hepatocytes. Cells were treated with agonist 
for the indicated times at 37°C. Cells were pelleted, lysed and pro-
tein kinases specifically immunoprecipitated as described Section 2. 
Data are an average of duplicates from representative experiments 
(n = 3) from immune-complex kinase assays and shown as -fold in-
creases in 32P-incorporation into substrate. Vehicle control values 
were r)47^A P kinase 
spectively. 
(25 500 ±750 cpm) and JNKI (950 ±70 cpm), re-
trated to 10 uM), or catalytic domain c/n/aPKC inhibitors 
GF109203X (titrated to 10 uM) and chelerythrine (titrated 
to 1 uM) blunted the ability of phenylephrine, but not 
E G F , to activate p 4 2
M A P k i ^ e (Fig. 2A). Pre-treatment of 
hepatocytes with the P K C inhibitors significantly reduced 
the ability of phenylephrine, but not E G F , to activate J N K I 
(Fig. 2B). Gq-coupled phenylephrine receptors are rapidly 
down-regulated in hepatocytes after isolation and primary 
culture [7], whereas Gq-coupled receptors for vasopressin 
are not. Pre-treatment of hepatocytes with the P K C inhibitors 
B 
% 
I 
Sphingosine GF109203X Chelerythrine 
y £ S 
treatment of cells with maximally inhibitory doses of the reg-
ulatory domain cPKC inhibitory effector, sphingosine (ti-
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Fig. 2. The role of PKC in the activation of (A) p42MAP kinase and 
(B) JNKI in freshly isolated hepatocytes, in response to phenyleph-
rine (phe) and epidermal growth factor (EGF) treatments. Freshly 
isolated hepatocytes were pre-treated (20 min, 37°C) with the maxi-
mally inhibitory doses of the PKC inhibitors sphingosine (10 |J,M), 
Ms-indolylmaleiamide (10 uM), chelerythrine (1.0 U.M), or vehicle 
before hormonal addition. After 20 min, cells were further treated 
with maximally stimulatory doses of phe (10 u,M) or EGF (30 ng/ 
ml) for 6 min at 37°C. Cells were pelleted, lysed and protein kinases 
specifically immunoprecipitated as described in Section 2. Data are 
an average of duplicates from three experiments using immune-com-
plex kinase assays and shown as -fold increases in 32P-incorporation 
into substrate. Vehicle control values were p42
MAPki™se (25 500 ±750 
cpm) and JNKI (950 ± 70 cpm), respectively. (C) Treatment of hep-
atocytes (20 min, 37°C) with ±PD98059 (50 iiM, +Lane 1, -Lane 
2) activates JNKI and stimulates AP-1 binding. AP-1 complex 
DNA binding was performed as described in Section 2 on 5 |xg of 
cellular lysate using non-denaturing gel electrophoresis. Lane 3, 
probe alone. 
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Fig. 3. The effects of sphingosine, chelerythrine, and PD98059 on the activities of (A) p42MAPkmase and (B) JNK1 in primary cultures hepato-
cytes (20 mm well). Primary cultured hepatocytes (12 well/20 mm dishes, 2x 105 cells) were treated for 20 min at 37°C with each of the PKC 
inhibitors (see Fig. 2), MEK1 inhibitor PD98059 (50 U.M), or vehicle control. Medium was aspirated, cells were lysed and protein kinases spe-
cifically immunoprecipitated as described in Section 2. Data are an average of duplicates from a representative experiment (« = 3) from im-
mune-complex kinase assays and shown as -fold increases in 32P-incorporation into substrate. Vehicle control values for freshly isolated hepato-
cytes were p42MAP kinase (20100 ±1000 cpm) and JNK1 (675 ±30 cpm), respectively. 
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did not inhibit the ability of vasopressin (10 nM) to cause 
elevation of the cytosolic levels of calcium in these cells 
(data not shown). 
Acute exposure of freshly isolated hepatocytes to maximally 
inhibitory doses of the PKC inhibitors sphingosine, 
GF109203X, or chelerythrine increased basal activity of 
JNK1, and reduced the basal activity of p42
M A P k i n a s e (Fig. 
2A,B). This disagrees with data of Beltman et al. [23] in 
Table 1 
Effect of inhibition of PKC and p42MAP kinase 
synthesis in primary cultured rat hepatocytes 
activities on DNA 
Condition -Fold [3H]thymidine incorporation 
Vehicle 
Chelerythrine (1 U.M) 
GF109203X (10 |xM) 
PD98059 (50 uM) 
1.00 ±0.06 
0.11 ±0.02* 
0.15 ±0.05* 
0.82 ±0.06* 
Hepatocytes isolated from rats were cultured in complete medium 
containing 2 uCi of [3H]thymidine as described in Section 2. Values 
shown are means ± SE, expressed as fold changes compared to buffer-
treated control cells (n = 17). Significant difference from corresponding 
buffer control value (*P<0.05). [3H]thymidine uptake in buffer-
treated controls was 3200 ± 200 cpm. 
Ratl fibroblasts which stated that GF109203X did not mod-
ulate JNK1/2 activity. Presumably, these differences are cell-
type specific. Acute treatment of cells with a maximally inhib-
itory dose of the inhibitor of MEK1 activation, PD98059 
(titrated to 50 uM), also reduced basal p42fc activity 
and increased JNK1 activity and AP-1 binding (Fig. 2C). 
These data suggest that inhibition of PKC, leading to inhib-
ition of p42MAP kmase function, causes an increase in the basal 
activity of JNK1 in adult rat hepatocytes. 
Time course studies (Fig. 1) revealed that while phenyleph-
rine caused an initial activation of JNK1, within 20-30 min 
the activities of these enzymes had fallen below that observed 
under control conditions. In contrast, the activity of 
p42MAP kmase fell to basal by 30 min post-phenylephrine stim-
ulation, but did not drop below this level (Fig. 1). The ability 
of phenylephrine to activate JNK1 was dependent upon PKC 
function as judged by multiple c/n/aPKC inhibitors; equally, 
inhibition of PKC function for 20 min promoted JNK1 acti-
vation. Since sphingosine, which inhibits c/nPKC but not 
aPKC isoforms, blocked the ability of phenylephrine to acti-
vate JNK1, we conclude that aPKC isoforms are not utilized 
by phenylephrine to stimulate JNK1 activity. Thus PKC ap-
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on a plate from a representative experiment (« = 3) and show the -fold increase in cells staining for PI. B: Apoptosis induced by chelerythrine 
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staining for PI. 
pears to play two separate roles within the same signaling 
pathway. First, inhibition of PKC reduced the ability of phen-
ylephrine to activate the SAP kinase pathway suggesting acute 
PKC function can positively modulate this signaling cascade. 
Second, inhibition of PKC increased the basal SAP kinase 
pathway activity, suggesting that PKC function also nega-
tively regulates these pathways. 
Activation of JNK1 activity by the PKC inhibitors was 
unexpected, as it reveals a conserved relationship between 
PKC and JNK1 activities. The importance of this observation 
with respect to regulation of cell survival is considerable. 
Acute stimulation of PKC by both pharmacological (e.g. 
phorbol esters) and physiological (e.g. diglyceride) activators 
attenuates or abolishes the initiation of apoptosis by numer-
ous ceramide-dependent stimuli [14,28,29]. Ceramide-medi-
ated apoptosis is subject to reciprocal modulation by diglycer-
ide and sphingoid bases in myeloid leukemia cells which 
respectively represent positive and negative physiological d 
nPKC effector molecules [14,28,29]. The regulation of PKC 
function thus appears to be a key point of convergence for 
these mutually opposing lipid messengers, and represents a 
critical node for the integration of upstream lipid signals. 
To extend these observations to primary cultures of hepa-
tocytes, cells were acutely exposed to the PKC inhibitory lipid 
sphingosine, the pharmacological PKC inhibitor cheleryth-
rine, and the MEK1 inhibitor PD98059, and p42
M A P k i n a s e 
and JNK1 activities measured (Fig. 3). Primary cultures of 
hepatocytes exhibited qualitatively similar effects to those ob-
served in freshly isolated cells after treatment with either 
sphingosine, chelerythrine, or PD98059 (Fig. 3). 
To examine the role PKC and p42MAP kinase function plays 
in the regulation of apoptosis, primary cultures of hepatocytes 
and HepG2 hepatoblastoma cells were treated for 4 h with 
either buffer control, sphingosine, iw-indolylmaleimide, chel-
erythrine, or the specific MEK1 inhibitor PD98059. Cell sur-
vival was assessed by uptake of the vital dye PI which stains 
non-intact necrotic cells (reflecting 1° necrosis) or late apop-
totic cells (reflecting 2° necrosis) [30]. 
Acute treatments (4 h) of primary cultures of hepatocytes 
with either sphingosine, GF109203X, or chelerythrine did not 
increase PI staining, but did significnatly increase staining of 
HepG2 cells (Fig. 4A). Acute treatment of primary cultures of 
hepatocytes and HepG2 cells with a maximally inhibitory 
dose of the MEK1 inhibitor PD98059 (50 uM) decreased 
basal p42MAP killase activities in both cell types by 80-90%, 
which was maintained for the next 4 h (data not shown). 
Treatment with PD98059 only caused a significant increase 
in PI staining in HepG2 cells (Fig. 4A). The combined effects 
on apoptosis of sphingosine and PD98059 co-treatment were 
less than additive (data not shown). Similar data were ob-
tained when other transformed cell types, e.g. U937 myeloid 
leukemia cells, were treated with these compounds (data not 
shown). These findings indicate that transformed cell lines 
may be more sensitive to apoptosis, via PKC inhibition and 
concominant reduction in p42MAPkinase function, than are 
non-transformed primary cultured hepatocytes. We conclude 
14 W.D. Jarvis et allFEBS Letters 412 (1997) 9-14 
that the sensitivities and mechanisms by which primary cul-
tures of hepatocytes and transformed HepG2 cells undergo 
apoptosis are different. 
Fur ther additional experiments then examined the abilities 
of chelerythrine, GF109203X, and PD98059 treatments to 
modulate proliferation of primary cultures of hepatocytes 
over a longer period of time. Maximally effective doses of 
chelerythrine and GF109203X which cause apoptosis in 
HepG2 cells but not primary cultures of hepatocytes after 
4 h, reduced the ability of primary cultured hepatocytes to 
proliferate (Table 1) and caused apoptosis after 48 h (Fig. 
4B). Treatment with PD98059, which reduced basal 
p42MAP kinase a c t j v j t y by 80-90%, had a small effect on the 
ability of hepatocytes to proliferate (Table 1), and did not 
cause apoptosis in these cells (Fig. 4B). These data demon-
strate that (a) inhibition of P K C in primary cultures of hep-
atocytes for 48 h, but not 4 h, causes apoptosis; (b) chronic 
inhibition of p42 M A P kinase by PD98059 does not dramatically 
reduce proliferative potential or cause apoptosis in primary 
cultures of hepatocytes; and (c) inhibition of p42 M A P k l n a s e 
function in transformed hepatocytes is sufficient to cause cell 
death, but that inhibition of p42 M A P k m a s e in non-transformed 
hepatocytes does not. However, since chronic inhibition of 
P K C caused apoptosis in primary cultures of hepatocytes, 
we can dissociate inhibition of P K C function from inhibition 
of p42 M A P k m a s e function as the key step in causing apoptosis in 
non-transformed primary cultures of hepatocytes. Overall, 
data suggest that non-transformed primary cultures of hepa-
tocytes are more resistant to apoptotic signals than are trans-
formed cells, which may permit better design of chemothera-
peutic treatments. 
D a t a presented in the present report suggest that the activ-
ities of P K C , p 4 2
M A P k i n a s e , and J N K 1 are in tightly regulated 
by multiple stimuli, and that it is the balance of regulatory 
signals emanating from these enzymes which determines cell 
fate. Our data suggests that the ability of P K C to modulate 
downstream signaling pathways is potentiated by cellular 
transformation. These mechanisms may thus represent a gen-
eral signaling paradigm through which information flow along 
multiple signaling pathways is integrated to produce an ob-
served physiological response. 
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